Results 41 to 50 of about 7,470 (208)

Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: Motor or sensory actions?

open access: yes
Antimuscarinic drugs are generally thought to exert their therapeutic action on detrusor overactivity by reducing the ability of the detrusor muscle to contract.
Gillespie JI   +3 more
core   +4 more sources

The Benefits of Adding Non‐Antimuscarinic Pharmaceuticals in Combination With Beta‐3 Agonists for Overactive Bladder Treatment: A Systematic Review

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Antimuscarinics, as the current first‐line pharmacologic therapies for overactive bladder, exhibit low patient adherence and high rates of reported side effects. As a modern alternative pharmaceutical treatment, beta‐3 agonists, which relax the urinary bladder, may be more tolerable for patients, increasing adherence and ...
Felicity Smith   +2 more
wiley   +1 more source

Investigation of the mechanisms and modulation of irinotecan‐induced emesis in Suncus murinus

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Irinotecan is a widely used chemotherapeutic agent that frequently causes nausea and emesis. Its emetic mechanism of action is poorly understood and the choice of drugs to reduce nausea and emesis is largely empirical. Experimental Approach Using Suncus murinus, we examined (i) the dose–response and temporal profile of ...
Zengbing Lu   +7 more
wiley   +1 more source

The effectiveness of intravesical oxybutynin in the management of overactive bladder: a clinical study

open access: yesUrogynaecologia International Journal
Overactive bladder (OAB) syndrome is a chronic, debilitating disorder with physical, psychological, and social repercussions that considerably reduces the quality of life for 12-17% of the population.
Shoeb Alahmad   +3 more
doaj   +1 more source

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

open access: yesBMC Urology, 2017
Background To assess treatment persistence and adherence in men ≥45 years of age with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), using prescription records from the Netherlands IMS Lifelink™ LRx database ...
Marcus J. Drake   +6 more
doaj   +1 more source

Correlation between the NGF levels and questionnaire forms in patients receiving antimuscarinic treatment and those receiving onabotulinum toxin-A injection

open access: yesUrology Research and Practice, 2021
Objective: To compare nerve growth factor (NGF) levels in patients who received antimuscarinic, versus onabotulinum toxin-A (onaBoNT-A) injection, as well as to investigate whether there is a correlation between NGF levels, and 8-item overactive bladder ...
Süleyman Sağır   +5 more
doaj   +1 more source

Impact of COVID‐19 and Vaccination on Lower Urinary Tract Symptoms: Insights From a Prospective Cohort Study

open access: yesNeurourology and Urodynamics, Volume 45, Issue 8, Page 1692-1700, November 2026.
ABSTRACT Aims To evaluate the prevalence, clinical course, and risk factors of lower urinary tract symptoms (LUTS) in patients hospitalized with COVID‐19, and to assess associations with comorbidities, disease severity, and vaccination status. Methods We conducted a prospective cohort study of adult patients hospitalized with confirmed COVID‐19, who ...
Julia Duarte de Souza   +12 more
wiley   +1 more source

“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox

open access: yesNeurourology and Urodynamics, Volume 45, Issue 8, Page 1479-1481, November 2026.
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan   +2 more
wiley   +1 more source

Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?

open access: yes, 2006
Antimuscarinic drugs are generally thought to exert their therapeutic action on detrusor overactivity by reducing the ability of the detrusor muscle to contract.
Finney, Steven M.   +4 more
core   +1 more source

Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment [PDF]

open access: yesInvestigative and Clinical Urology, 2017
Purpose: To identify incidence and risk factors of recurrence after discontinuation of successful antimuscarinic therapy in patients with overactive bladder (OAB). Materials and Methods: This was a prospective, multicenter trial.
Aram Kim   +17 more
doaj   +1 more source

Home - About - Disclaimer - Privacy